Alteration of HER2 Status Following Neoadjuvant Chemotherapy in Breast Cancer: A Clinicopathological Analysis Focusing on HER2-Low Status
Given the prognostic implications of HER2 discordance which primarily involves zero-to-low conversion and the therapeutic benefits of newly developed antibody-drug conjugates in HER2-low breast cancers, HER2 status should be re-evaluated in surgical resection specimens following NAC.
Authors
- Koung Jin Suh (ORCID: https://orcid.org/0000-0002-1881-8738)
- Hyun Jung Kwon (ORCID: https://orcid.org/0000-0001-8822-7899)
- Yul Ri Chung (ORCID: https://orcid.org/0000-0001-9501-8657)
- Se Hyun Kim (ORCID: https://orcid.org/0000-0002-2292-906X)
- Hee-Chul Shin (ORCID: https://orcid.org/0000-0001-6096-0845)
- Jee Hyun Kim (ORCID: https://orcid.org/0000-0003-1336-3620)
- So Yeon Park (ORCID: https://orcid.org/0000-0002-0299-7268)
- Hyun-Jung Sung (ORCID: https://orcid.org/0000-0002-8791-5945)
- Eun-Kyu Kim
- Kyungah Bai
Institutions
- Seoul National University Bundang Hospital (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-09-19
- DOI
- https://doi.org/10.4143/crt.2025.761
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94